Roche acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance technology development for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood. CAPP Medical's technology is designed to isolate and quantify small amounts of ctDNA through a simple blood draw, which has the potential to be used for cancer therapy selection and monitoring tumor response and resistance to therapy, according to Roche officials.

“Roche believes focused and high quality next generation sequencing assays using simple blood draws have the potential to significantly advance the time of cancer diagnosis and change routine cancer diagnostic monitoring and may be highly cost effective compared to today's current standard of using PET and CT imaging to monitor tumor progression,” said Roland Diggelmann, COO Roche Diagnostics. “CAPP Medical's technology for detecting the circulating cancer DNA from blood has the potential to further strengthen Roche's diagnostic offerings for patients and will provide valuable clinical trial support for Pharma oncology pipelines.”

Previous articleHuman Norovirus Books Dog Cruise, May Have Return Ticket
Next articleDiverse Pathways to Drug Targets